Literature DB >> 20472107

The bone remodeling environment is a factor in breast cancer bone metastasis.

Li Laine Ooi1, Yu Zheng, Kellie Stalgis-Bilinski, Colin R Dunstan.   

Abstract

The bone microenvironment is clearly an important determinant of breast cancer metastasis to bone. Once established in bone, the ability for breast cancer cells to hijack normal regulatory pathways for osteoclast differentiation, activation, and survival is known to form the basis of a vicious cycle that promotes both bone destruction and tumor growth. However, the importance of the background remodeling activity in the early stages of breast cancer metastatic establishment in bone has not been systematically investigated. Here we review recent studies that indicate that bone remodeling levels, as influenced by calcium and vitamin D status, do impact the ability of human breast cancer cells to grow in the bones of nude mice. These studies support the assessment and correction of calcium and vitamin D deficient states in women at risk of developing advanced breast cancer.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472107     DOI: 10.1016/j.bone.2010.05.007

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  14 in total

1.  CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone.

Authors:  Véronique Ouellet; Kerstin Tiedemann; Anna Mourskaia; Jenna E Fong; Danh Tran-Thanh; Eitan Amir; Mark Clemons; Bernard Perbal; Svetlana V Komarova; Peter M Siegel
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway.

Authors:  Ya-Ling Hsu; Ming-Shyan Huang; Chih-Jen Yang; Jen-Yu Hung; Ling-Yu Wu; Po-Lin Kuo
Journal:  J Biol Chem       Date:  2011-09-01       Impact factor: 5.157

3.  Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis.

Authors:  Valeria B Fernández Vallone; Erica L Hofer; Hosoon Choi; Raúl H Bordenave; Emilio Batagelj; Leonardo Feldman; Vincent La Russa; Daniela Caramutti; Federico Dimase; Vivian Labovsky; Leandro M Martínez; Norma A Chasseing
Journal:  Clin Exp Metastasis       Date:  2012-09-30       Impact factor: 5.150

4.  Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation.

Authors:  Celeste Bolin; Ken Tawara; Caleb Sutherland; Jeff Redshaw; Patrick Aranda; Jim Moselhy; Robin Anderson; Cheryl L Jorcyk
Journal:  Genes Cancer       Date:  2012-02

5.  Multimodality imaging of tumor and bone response in a mouse model of bony metastasis.

Authors:  Benjamin A Hoff; Komal Chughtai; Yong Hyun Jeon; Kenneth Kozloff; Stefanie Galbán; Alnawaz Rehemtulla; Brian D Ross; Craig J Galbán
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

6.  Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone.

Authors:  Yu Zheng; Dennis Basel; Shu-Oi Chow; Colette Fong-Yee; Sarah Kim; Frank Buttgereit; Colin R Dunstan; Hong Zhou; Markus J Seibel
Journal:  Clin Exp Metastasis       Date:  2014-09-16       Impact factor: 5.150

Review 7.  Reader's digest of the pathophysiology of bone metastases.

Authors:  Reinhard Gruber
Journal:  Wien Med Wochenschr       Date:  2012-07-14

Review 8.  Breast cancer metastasis to the bone: mechanisms of bone loss.

Authors:  Yu-Chi Chen; Donna M Sosnoski; Andrea M Mastro
Journal:  Breast Cancer Res       Date:  2010-12-16       Impact factor: 6.466

9.  CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis.

Authors:  Véronique Ouellet; Peter M Siegel
Journal:  J Cell Commun Signal       Date:  2012-03-18       Impact factor: 5.782

10.  The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer.

Authors:  Nigel T Brockton; Stephanie J Gill; Stephanie L Laborge; Alexander H G Paterson; Linda S Cook; Hans J Vogel; Carrie S Shemanko; David A Hanley; Anthony M Magliocco; Christine M Friedenreich
Journal:  BMC Cancer       Date:  2015-07-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.